Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
The Oncologist|January 23, 2025
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancerFerdinandos Skoulidis, Bob T Li, Maximilian Hochmair, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutationsRafael Rosell, Miguel Angel Molina, Carlota Costa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2026
Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung CancerBelén Sierra-Rodero, Ángeles Gil-González, Marta Molina-Alejandre, et al.
Molecular Oncology|November 25, 2020
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancerCristina Aguado, Cristina Teixido, Ruth Román, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
JTO Clinical and Research Reports|March 25, 2024
RET Fusion Testing in Patients With NSCLC: The RETING StudyEsther Conde, Susana Hernandez, Jose Luis Rodriguez Carrillo, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
Journal of the National Cancer Institute|April 5, 2017
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLCImane Chaib, Niki Karachaliou, Sara Pilotto, et al.
Lung Cancer (Amsterdam, Netherlands)|August 18, 2020
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patientsNir Peled, Roni Gillis, Saadettin Kilickap, et al.
Pageof 8